Amy Simpson-Waid
Acute Care · Gulfport, MSNPI 1710209184
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 481 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$844
- GSK$813
- Amgen$732
- AstraZeneca$696
- AbbVie$534
- Novo Nordisk$534
- plus $3K from 34 others
What the payments were for
- Food & beverage$7,506100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,516 in reported general payments places this provider in the 90th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $108,567 |
| MounjaroTirzepatide | 74 | $96,591 |
| JardianceEmpagliflozin | 66 | $78,035 |
| TrulicityDulaglutide | 35 | $63,231 |
| OzempicSemaglutide | 42 | $49,323 |
| FarxigaDapagliflozin Propanediol | 47 | $40,306 |
| EliquisApixaban | 52 | $34,746 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $22,686 |
| JanuviaSitagliptin Phosphate | 16 | $19,477 |
| XareltoRivaroxaban | 20 | $19,218 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $18,581 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $14,334 |
| LinzessLinaclotide | 20 | $12,275 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $10,167 |
| KerendiaFinerenone | 12 | $9,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $844 | $159,821109 claims |
| Boehringer IngelheimJardiance | $235 | $78,03566 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $696 | $54,63958 claims |
| Novo NordiskOzempic | $534 | $49,32342 claims |
| PfizerEliquis | $232 | $34,74652 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $813 | $23,92326 claims |
| MerckJanuvia | $147 | $19,47716 claims |
| Johnson & JohnsonXarelto | $121 | $19,21820 claims |
| AbbVieLinzess | $534 | $12,27520 claims |
| BayerKerendia | $282 | $9,09912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 acute care providers in Mississippi.
Other acute care in Gulfport
- Michelle TaylorGulfport$13K
- Elizabeth ColemanGulfport$4K
- Christopher BellTupelo$348K
- Kathleen ArnoldOcean Springs$217K
- Gavin GistOxford$42K
- Jamie DamicoOcean Springs$17K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Aaron KatzenmeyerMadison$12K
- Megan WilliamsTupelo$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.